

2 October 2009

Dear Shareholder


ANNUAL GENERAL MEETING

I am pleased to invite you to attend the Annual General Meeting of Bionomics Limited to be held at 2.00pm on Wednesday 4 November 2009, in the Marble Room, the Radisson Plaza Hotel, 27 O'Connell Street, Sydney, and have enclosed the Notice of Meeting and Explanatory Memorandum.

If you are unable to attend the meeting in person, I encourage you to return the enclosed proxy form. The proxy form should be returned in the envelope provided, or faxed to our Share Registry on (08) 8236 2305 so that it is received by 2.00 pm on Monday 2 November 2009.

I look forward to your attendance at the meeting.

Yours sincerely



Peter Jonson
Chairman



NOTICE OF ANNUAL GENERAL MEETING 2009

Notice is hereby given that the Annual General Meeting of Bionomics Limited ("the Company") will be held in the Marble Room, The Radisson Plaza Hotel, 27 O'Connell Street, Sydney, New South Wales, at 2.00pm on Wednesday 4 November 2009 to transact the business set out below.

Members should refer to the accompanying Explanatory Notes for further information concerning the business to be transacted at this meeting.

ORDINARY BUSINESS

Financial Statements and Reports

To receive and consider the Company's Financial Report for the financial year ended 30 June 2009 and the accompanying Directors' Report and Auditor's Report.

An electronic copy of the Company's financial report is available on our website www.bionomics.com.au.

Resolution 1 – Adoption of Remuneration Report

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That the remuneration report for the year ended 30 June 2009 be adopted.

Please note that the vote on this resolution is advisory only and does not bind the directors or the Company.

Resolution 2 – Re-election of Non-Executive Director – Mr Trevor Tappenden

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That Mr Trevor Tappenden be re-elected as a director of the Company.

Mr Tappenden will be retiring at the Annual General Meeting as required by the Company's Constitution and, being eligible, offers himself for re-election.

Resolution 3 – Election of Non-Executive Director – Mr Christopher Fullerton

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That Mr Christopher Fullerton be elected as a director of the Company.

Mr Fullerton, having been appointed by the directors since the last Annual General Meeting, will be retiring at the Annual General Meeting as required by the Company's Constitution and, being eligible, offers himself for election.

SPECIAL BUSINESS

Resolution 4 – Approval of Proposed Issue of Shares to Directors

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, the issue of fully paid ordinary shares in the Company to the following directors in the quantities specified below and on the terms described in the Explanatory Notes accompanying the Notice of this Annual General Meeting is approved:

<i>Dr Peter Jonson</i>	<i>39,729</i>
<i>Dr Deborah Rathjen</i>	<i>192,000</i>
<i>Mr Trevor Tappenden</i>	<i>57,544</i>
<i>Dr Errol De Souza</i>	<i>76,935</i>
<i>Mr Christopher Fullerton</i>	<i>125,020</i>

Resolution 5 – Approval of Proposed Issue of Share Options to Mr Christopher Fullerton

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That, for the purposes of ASX Listing Rules 7.1 and 10.14 and for all other purposes, the issue to Mr Fullerton of 500,000 share options in the Company pursuant to the Bionomics Limited Employee Share Option Plan, as described in the Explanatory Notes accompanying the Notice of this Annual General Meeting, is approved.

VOTING EXCLUSION STATEMENT

1. In relation to Resolution 4, in accordance with Listing Rule 14.11 of the ASX Listing Rules, the Company will disregard any votes cast on the Resolution by or on behalf of Dr Peter Jonson, Dr Deborah Rathjen, Mr Trevor Tappenden, Dr Errol De Souza or Mr Christopher Fullerton and any person who might obtain a benefit, except a benefit solely in the capacity of a holder of ordinary securities, if the Resolution is passed, as well as any associate of any of the above.
2. In relation to Resolution 5, in accordance with Listing Rule 14.11 of the ASX Listing Rules, the Company will disregard any votes cast on the Resolutions by or on behalf of a director of the Company and any person who might obtain a benefit, except a benefit solely in the capacity of a holder of ordinary securities, if the Resolutions are passed, as well as any associate of any of the above.

Despite the foregoing, the Company is not required to disregard a vote if (a) it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or (b) by the Chairman of the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

PROXIES, POWERS OF ATTORNEY AND CORPORATE REPRESENTATIVES

A member who is entitled to attend and vote at this meeting may appoint a proxy to attend and vote for the member at the meeting. The proxy need not be a member of the Company and may be an individual or a body corporate. For the convenience of members a proxy appointment form is enclosed.

A member who is entitled to cast more than one vote at the meeting may appoint two separate proxies to vote on their behalf. Where two proxies are appointed, the member may specify the proportion or number of votes each proxy is appointed to exercise failing which each proxy may exercise half of the member's votes. Fractions of votes will be disregarded. If a single proxy is appointed by a member that proxy may vote on a show of hands. If two proxies are appointed by a member, neither proxy may vote on a show of hands.

An appointed proxy has the same rights as the member to speak at the meeting and to join in a demand for a poll.

In order to record a valid vote, members will need to take the following steps:

- Cast your vote online by visiting www.investorvote.com.au and following the instructions and information provided on the enclosed proxy form; or
- Custodian voting - For Intermediary Online subscribers only (custodians) please visit www.intermediaryonline.com to submit your voting intentions; or
- Complete and lodge the Proxy Form with the Company at the address or facsimile number specified below, along with any power of attorney or notarially certified copy of a power of attorney (if the proxy form is signed pursuant to a power of attorney)

By no later than 48 hours before the Annual General Meeting (ie by no later than 2.00pm 2 November 2009):

Bionomics Limited
c/- Computershare Investor Services Pty Ltd
GPO Box 242
MELBOURNE VIC 3001

A member who is a body corporate may appoint an individual as a representative to exercise the member's voting rights at the Annual General Meeting pursuant to section 250D of the Corporations Act. Representatives will be required to present documentary evidence of their appointment on the day of the meeting.

DETERMINATION OF ENTITLEMENT TO ATTEND AND VOTE

For the purpose of the Corporations Act, the Company has determined that all securities of the Company that are quoted securities at 7.00pm (Adelaide time) on 2 November 2009 will be taken, for the purpose of the Annual General Meeting, to be held by the persons who held them at that time.

QUESTIONS AND COMMENTS BY MEMBERS

In accordance with the Corporations Act, the Chairperson of the Annual General Meeting will allow a reasonable opportunity for members at the meeting to ask questions about, or make comments on, the management of the Company.

Similarly, the Chairperson will allow a reasonable opportunity for members at the meeting to ask questions of a representative of the Company's Auditors, Deloitte Touche Tohmatsu, relevant to the conduct of the audit, the preparation and content of the Auditor's Report, the accounting policies adopted by the Company in relation to the preparation of the financial statements and the independence of the Auditors in relation to the conduct of the audit.

Pursuant to the Corporations Act, members may submit a written question to the Company's Auditors relevant to the content of the Auditor's Report to be considered at the Annual General Meeting or the conduct of the audit of the Financial Report to be considered at the Annual General Meeting.

Questions to the Company's Auditors must be given to the Company no later than Wednesday 28 October 2009. The Company may examine the contents, or make a copy, of any question so submitted. A list of relevant written questions (prepared by the Company's Auditors) will be made available to members attending the Annual General Meeting at the start of the meeting.

The Chairperson of the Annual General Meeting will allow a reasonable opportunity at the meeting for a representative of the Company's Auditors to answer any written questions submitted in accordance with the above procedure. If the Company's Auditor has prepared written answers to written questions, the Chairperson may allow these to be tabled at the meeting and such written answers will be made available to members as soon as practicable after the meeting.

Please send any written questions for the Company's Auditors to:

Bionomics Limited
31 Dalgleish Street
Thebarton SA 5031
or facsimile: (08) 8354 6199
or email: info@bionomics.com.au

by no later than 5:00pm (Adelaide time) on Wednesday 28 October 2009.

By order of the Board

Stephen Birrell
Company Secretary

Adelaide 2 October 2009



EXPLANATORY NOTES FOR THE 2009 ANNUAL GENERAL MEETING

These Explanatory Notes have been prepared to assist shareholders with their consideration of the resolutions set out in the Notice of Annual General Meeting dated 2 October 2009.

ORDINARY BUSINESS

RESOLUTION 1: Adoption of Remuneration Report

The remuneration report for the year ended 30 June 2009 is set out in the 2008-09 financial statements, which is available on Bionomics' website at www.bionomics.com.au.

Pursuant to section 250R(2) of the Corporations Act, a resolution that the remuneration report be adopted must be put to the vote at the Company's Annual General Meeting. The vote on the proposed resolution is advisory only and does not bind the directors or the Company. However, the Board will take the outcome of the vote into consideration when reviewing the Company's remuneration practices and policies.

The chairman will allow a reasonable opportunity for members to discuss the remuneration report.

RESOLUTION 2: Re-election of Non-Executive Director

Mr Trevor Tappenden will retire at the Annual General Meeting as required by the Company's Constitution and, being eligible, offers himself for re-election.

Mr Tappenden was appointed to the Board on 15 September 2006 and elected at the AGM held on 9 November 2006.

Mr Tappenden was a partner of Ernst & Young between 1982 and 2003, holding a variety of positions including Managing Partner of the Melbourne Office, member of the Board of Partners, head of the Victorian Government Services Group and National Director of the Entrepreneurial Services Division. Mr Tappenden is a director of Public, Private, Government, and not-for-profit organisations, is Chairman of Heide Museum of Modern Art, and a Councillor of RMIT University. He is the Chairman of the Audit and Risk Management Committees of many of those organisations.

RESOLUTION 3: Election of Non-Executive Director

Mr Christopher Fullerton, having been appointed by the directors since the last Annual General Meeting, will retire at the Annual General Meeting as required by the Company's Constitution and, being eligible, offers himself for election.

Mr Fullerton was appointed to the Board on 23 December 2008.

Mr Fullerton has extensive experience in investment, management and investment banking and is a qualified chartered accountant. He is the managing director of Mandalay Capital Pty Limited, an investor in listed securities and private equity and a director of Avanti Capital Limited, an advisory firm focusing on the life sciences sector. Mr Fullerton was non-executive chairman of Cordlife Limited and Health Communication Network Limited, and held non executive directorships with Global Health Limited, The Environmental Group Limited, Standard Chartered Australia Limited, Alliance Properties Limited and Federal Airports Corporation.

SPECIAL BUSINESS

BACKGROUND

Resolutions 4 and 5 set out in the Notice of Annual General Meeting are being put before shareholders for the purpose of ASX Listing Rules 7.1, 10.11 and 10.14 (as applicable) and for all other purposes.

(A) *Listing Rules 7.1 and 7.2 (exception 9)*

Broadly speaking, Listing Rule 7.1 provides that a listed company may issue or agree to issue in aggregate up to 15% of its fully paid ordinary shares within a 12-month period without shareholder approval. Any issues of shares beyond this amount must be first approved by shareholders and any issues of shares otherwise approved by shareholders will not be counted in calculating compliance with the 15% limit. If shareholders approve the issue of share options to Mr Christopher Fullerton (Resolution 5), the issue of those share options will not be counted in calculating compliance with the 15% limit.

(B) *Listing Rule 10.11*

Listing Rule 10.11 requires a listed company to obtain shareholder approval for the issue of securities to related parties. As a consequence, the Company is required to obtain shareholder approval before issuing shares to its directors and any company controlled by a director (Resolution 4).

The 15% limit imposed by Listing Rule 7.1 does not include issues approved under Listing Rule 10.11 (because of Listing Rule 7.1, Exception 14) and shareholders should note that, if they pass Resolution 4, it is not necessary for the Company to seek separate shareholder approval of the proposed share issues under Listing Rule 7.1.

(C) *Listing Rule 10.14*

Listing Rule 10.14 requires a listed company to obtain shareholder approval for the issue of securities under an employee incentive scheme (such as the Bionomics Employee Option Plan) to certain parties, which includes a director, or an associate of a director, of the Company. As a consequence, the Company is required to obtain shareholder approval before issuing share options to Mr Christopher Fullerton under the Bionomics Employee Share Option Plan (Resolution 5).

RESOLUTION 4: ASX Listing Rule 10.11 – Proposed Issue of Shares to Directors

Resolution 4 is being put before shareholders for the purpose of ASX Listing Rule 10.11 and for all other purposes.

As noted above, ASX Listing Rule 10.11 requires a listed company to obtain shareholder approval for the issue of securities to related parties, which includes a director of the Company. ASX Listing Rule 10.13 sets out the information that must be included in the Notice of Annual General Meeting when seeking approval of shareholders under ASX Listing Rule 10.11.

Under Resolution 4, the Board seeks approval to issue shares to each of the Company's non-executive directors in lieu of one third of their directors' fees, and to Dr Deborah Rathjen (Chief Executive Officer and Managing Director) in lieu of some of her annual salary, for the financial year ending on 30 June 2010 ("**Payment Period**").

The Board believes this is beneficial for the Company since it conserves the Company's cash reserves and further aligns directors' interests with the interests of shareholders.

Shareholders have approved the issue of shares to non-executive directors in this manner at the last eight Annual General Meetings.

Shareholders have approved the issue of shares to Dr Deborah Rathjen in this manner at the last three Annual General Meetings. It is evident of her commitment to the company that she is prepared to sacrifice cash for shares in order to preserve the working capital of the Company.

The following information is provided for the purposes of ASX Listing Rule 10.13.

The Board has used a volume weighted average share price (VWAP) to calculate the number of shares to be issued in lieu of one third of the directors' fees payable and in lieu of annual salary for Dr Deborah Rathjen, for the Payment Period. The VWAP used in respect of the Payment Period has been calculated by reference to the price at which shares traded on the Australian Securities

Exchange using the same formulae as the Bionomics Limited Employee Share Option Plan which has previously been approved by shareholders. The weighted average price used is the 7 day VWAP which was \$0.2375 over the 7 trading days immediately preceding 31 August 2009.

The non-executive directors' fees payable to current directors in respect of the Payment Period are:

	1 July 2009 to 30 June 2010
Chairman	\$82,000
Directors	\$41,000

Based on one third of these amounts for non-executive directors and some of Dr Rathjen's annual salary, the number of shares proposed to be issued to each director under the arrangement described above is as follows:

Director	With respect to financial year ending 30 June 2010
Dr Peter Jonson	39,729
Mr Trevor Tappenden	57,544
Dr Errol De Souza*	76,935
Mr Christopher Fullerton*	125,020
Dr Deborah Rathjen	192,000
*Mr Fullerton and Dr De Souza are receiving additional shares due to their appointment dates being pro-rata last financial year and Mr Fullerton assuming the Chairmanship.	

The Company proposes to issue the above shares by no later than 4 December 2009. The shares to be issued will carry the usual rights applicable to ordinary shares in the Company and will, from their date of issue, rank equally with fully paid ordinary shares currently on issue.

As the shares will be issued in lieu of directors' fees and salary, no funds will be raised by the issue of the shares. However, the Company expects that the money saved will be used for the Company's research and development projects.

RESOLUTION 5 – ASX Listing Rule 10.14 - Proposed Issue of Share Options to Mr Christopher Fullerton

Resolution 5 seeks shareholder approval for the proposed issue of share options to Mr Christopher Fullerton.

Resolution 5 is being put to Shareholders for the purposes of ASX Listing Rules 7.1 and 10.14 and for all other purposes.

Under the Australian Securities Exchange Corporate Governance Principles and Recommendations, the guidelines for non-executive director remuneration provide that non-executive directors should normally be remunerated by way of fees, should not participate in schemes designed for remuneration of executives and should not receive options.

However, in view of the special circumstances of the Company, namely:

- the Company does not presently have earnings and its cash is at a premium; and
- the Company considers it essential to attract and retain high calibre non-executive directors and to provide those directors with a competitive level of remuneration,

the issue of options is in the best interests of the Company, and aligns the interests of non-executive directors with the interests of the Company's shareholders.

The Company proposes to issue share options to Mr Fullerton as follows:

<i>Non-Executive Director</i>	<i>Number of Share Options</i>	<i>Exercise Period</i>
Mr Christopher Fullerton	500,000	<ul style="list-style-type: none"> • for 100,000 options, a 5 year period commencing from the first anniversary of the date of acceptance; • for 100,000 options, a 5 year period commencing from the second anniversary of the date of acceptance; • for 100,000 options, a 5 year period commencing from the third anniversary of the date of acceptance; • for 100,000 options, a 5 year period commencing from the fourth anniversary of the date of acceptance; and • for 100,000 options, a 5 year period commencing from the fifth anniversary of the date of acceptance.

The following information is provided in relation to the terms of the share options and for the purposes of ASX Listing Rules 7.3 and 10.15:

- (a) the share options will be issued under the Bionomics Limited Employee Share Option Plan ("**Option Plan**") for no consideration (but with an exercise price as described below);
- (b) each share option entitles Mr Fullerton to subscribe for a fully paid ordinary share in the Company at a price of \$0.30 per share at any time during the share option exercise period as described in the table above;
- (c) since the last approval of the issue of securities under the Option Plan (approved pursuant to Listing Rule 10.14) Dr Deborah Rathjen has received 1,095,000 options and Dr Errol De Souza has received 500,000. These options were issued for no consideration. These options were the options approved by shareholders at the Annual General Meeting of the Company on 5 November 2008.
- (d) the directors of the Company as listed below are each entitled to participate in the Option Plan:
 - Dr Peter Jonson
 - Dr Deborah Rathjen
 - Mr Trevor Tappenden
 - Dr Errol De Souza
 - Mr Christopher Fullerton
- (e) a voting exclusion statement in respect of Resolution 5 is set out in the Notice of Annual General Meeting;
- (f) there is no loan in relation to the acquisition by Mr Fullerton;
- (g) if Resolution 5 is approved, the share options are expected to be issued by 4 December 2009 (and in any event, no later than 4 February 2010); and
- (h) the share options will be issued for no consideration and therefore no funds will be raised by the issue of the share options. However, to the extent that the share options are exercised, the Company expects that the funds raised by the issue will be used for the Company's research and development projects.

The share options will not be quoted on the ASX.

Bionomics
ABN 53 075 582 740



Limited

000001 000 BNO
MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030

Lodge your vote:



Online:
www.investorvote.com.au



By Mail:
Computershare Investor Services Pty Limited
GPO Box 242 Melbourne
Victoria 3001 Australia

Alternatively you can fax your form to
(within Australia) 1800 783 447
(outside Australia) +61 3 9473 2555

For Intermediary Online subscribers only
(custodians) www.intermediaryonline.com

For all enquiries call:

(within Australia) 1300 850 505
(outside Australia) +61 3 9415 4000

Proxy Form



Vote online or view the annual report, 24 hours a day, 7 days a week:

www.investorvote.com.au



Cast your proxy vote



Access the annual report



Review and update your securityholding

Your secure access information is:

Control Number: 999999

SRN/HIN: 1999999999

PIN: 99999



PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

For your vote to be effective it must be received by 2:00 pm (Sydney Time) Monday 2 November 2009

How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

Appointment of Proxy

Voting 100% of your holding: Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote as they choose. If you mark more than one box on an item your vote will be invalid on that item.

Voting a portion of your holding: Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

Appointing a second proxy: You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

Signing Instructions for Postal Forms

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held.

Attending the Meeting

Bring this form to assist registration. If a representative of a corporate securityholder or proxy is to attend the meeting you will need to provide the appropriate "Certificate of Appointment of Corporate Representative" prior to admission. A form of the certificate may be obtained from Computershare or online at www.computershare.com.

Comments & Questions: If you have any comments or questions for the company, please write them on a separate sheet of paper and return with this form.

**GO ONLINE TO VOTE,
or turn over to complete the form** →

MR SAM SAMPLE
 FLAT 123
 123 SAMPLE STREET
 THE SAMPLE HILL
 SAMPLE ESTATE
 SAMPLEVILLE VIC 3030

Change of address. If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with 'X') should advise your broker of any changes.



I 9999999999

I ND

Proxy Form

Please mark to indicate your directions

STEP 1 Appoint a Proxy to Vote on Your Behalf

XX

I/We being a member/s of Bionomics Limited hereby appoint

the Chairman of the Meeting **OR**



PLEASE NOTE: Leave this box blank if you have selected the Chairman of the Meeting. Do not insert your own name(s).

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairman of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, as the proxy sees fit) at the Annual General Meeting of Bionomics Limited to be held in the Marble Room, The Radisson Plaza Hotel, 27 O'Connell Street, Sydney, New South Wales on Wednesday, 4 November 2009 at 2:00 pm and at any adjournment of that meeting.

Important for Item 4: If the Chairman of the Meeting is your proxy and you have not directed him/her how to vote on Item 4 below, please mark the box in this section. If you do not mark this box and you have not directed your proxy how to vote, the Chairman of the Meeting will not cast your votes on Item 4 and your votes will not be counted in computing the required majority if a poll is called on this Item. The Chairman of the Meeting intends to vote undirected proxies in favour of item 4 of business.

I/We acknowledge that the Chairman of the Meeting may exercise my proxy even if he/she has an interest in the outcome of that Item and that votes cast by him/her, other than as proxy holder, would be disregarded because of that interest.

STEP 2 Items of Business



PLEASE NOTE: If you mark the **Abstain** box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

ORDINARY BUSINESS

	For	Against	Abstain
1. Adoption of Remuneration Report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Re-election of Non-Executive Director – Mr Trevor Tappenden	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Election of Non-Executive Director – Mr Christopher Fullerton	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

SPECIAL BUSINESS

4. Approval of Proposed Issue of Shares to Directors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Approval of Proposed Issue of Share Options to Mr Christopher Fullerton	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business.

SIGN Signature of Securityholder(s) *This section must be completed.*

Individual or Securityholder 1

Sole Director and Sole Company Secretary

Securityholder 2

Director

Securityholder 3

Director/Company Secretary

Contact Name _____

Contact Daytime Telephone _____

Date ____/____/____